Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Clinician's Roundtable

ATHENA Trial: Reducing Cardiovascular Deaths By Preventing Recurrent Atrial Fibrillation

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    Can we reduce cardiovascular deaths by preventing a recurrence of atrial fibrillation?  Dr. Eric Prystowsky, Director of Electrophysiology at St. Vincent Hospital in Indianapolis, Indiana, will discuss the results of the ATHENA trial; a study using dronedarone, an amiodarone-like medication, that was shown to significantly reduce cardiovascular deaths and hospitalizations due to atrial fibrillation and acute coronary syndromes. Join host Dr. Matthew Sorrentino.

     

Recommended
Details
Presenters
Comments
  • Overview

    Can we reduce cardiovascular deaths by preventing a recurrence of atrial fibrillation?  Dr. Eric Prystowsky, Director of Electrophysiology at St. Vincent Hospital in Indianapolis, Indiana, will discuss the results of the ATHENA trial; a study using dronedarone, an amiodarone-like medication, that was shown to significantly reduce cardiovascular deaths and hospitalizations due to atrial fibrillation and acute coronary syndromes. Join host Dr. Matthew Sorrentino.

     

Schedule31 Oct 2024